Clarification Required: Term Does Not Exist in Medical Literature
The term "musculoskeletal dysplasia of the middle cerebral artery" does not exist in medical nomenclature and appears to be a conflation of unrelated conditions.
What You Likely Mean
Based on the anatomical location (middle cerebral artery) and the evidence provided, you are most likely referring to one of these distinct vascular conditions:
Fibromuscular Dysplasia (FMD) of the Middle Cerebral Artery
This is the most probable intended diagnosis. FMD is a non-atherosclerotic, non-inflammatory arteriopathy affecting medium-sized arteries, including rarely the intracranial vessels 1, 2.
Evaluation for Intracranial FMD:
- Brain MRI with MRA (without contrast) is the recommended first-line imaging to diagnose intracranial FMD and assess for complications 3, 4
- Digital subtraction angiography (DSA) remains the gold standard for definitive diagnosis, showing the classic "string-of-beads" appearance or focal stenosis 1, 2, 4
- Mandatory head-to-pelvis vascular imaging (CTA or MRA) is required to detect multivessel involvement, as FMD is frequently multifocal 4, 5
- Screen for intracranial aneurysms (present in 7% of FMD patients) and cervical artery dissection (7-17% prevalence) 4, 6
Management Strategy:
Antiplatelet therapy is the cornerstone of medical management for cerebrovascular FMD to prevent thromboembolic complications 3, 2, 4. Specifically:
- Aspirin 81-325 mg daily is reasonable as first-line therapy 3
- Clopidogrel 75 mg daily is an alternative 3
- Strict blood pressure control is essential, targeting normal range to reduce arterial wall stress 3, 5
- Statins are NOT routinely indicated unless there are standard cardiovascular indications 5
- Smoking cessation is mandatory 5
Endovascular intervention (angioplasty with or without stenting) should be considered only for:
Critical pitfall: Endovascular treatment of intracranial FMD carries significant risks and should only be performed at specialized centers 4. Unlike renal FMD, intracranial intervention has limited evidence and higher complication rates.
Surveillance:
- Annual non-invasive vascular imaging initially to detect disease progression, then less frequently once stability is confirmed 3, 5
- Immediate imaging (MRI within 2 weeks) for any new neurological symptoms suggesting stroke, TIA, or dissection 4, 6
- One-time screening of first-degree relatives may be considered, though routine genetic testing is not indicated 5
Alternative Diagnoses to Exclude:
If the patient has bilateral stenosis of the MCA with moyamoya collaterals, this is Moyamoya Angiopathy, not FMD:
- Requires DSA for diagnosis 7, 8
- Management involves surgical revascularization (direct or indirect bypass) for symptomatic patients 7, 8
- Medical therapy alone is insufficient for preventing stroke 7
If imaging shows arteriovenous malformation (AVM) rather than arterial stenosis:
- Requires multidisciplinary evaluation for potential embolization, surgery, or radiosurgery 9, 10
- Management depends on Spetzler-Martin grade 10
If imaging shows cavernous malformation (CCM):
- MRI with gradient echo or susceptibility-weighted sequences is diagnostic 11
- Catheter angiography is NOT recommended 11
Bottom Line
Clarify the actual diagnosis first. If this is intracranial FMD affecting the MCA, initiate antiplatelet therapy immediately, perform comprehensive vascular imaging from head to pelvis, control blood pressure aggressively, and refer to a specialized FMD center for long-term management 4, 5. Reserve endovascular intervention only for medically refractory cases at experienced centers.